This site is intended for healthcare professionals
Drug news

Revance Therapeutics to initiate Phase III trial for RT 001 for treatment of Facial Wrinkles

Read time: 1 mins
Last updated:4th Apr 2013
Published:4th Apr 2013
Source: Pharmawand

Revance Therapeutics inc has secured the funding necessary to initiate a Phase III trial for Botulinum Toxin Type A Topical Gel for the treatment of facial wrinkles (crows feet) that is intended to compete with injected therapies such as Botox.

RT 001 is also currently in Phase II trials for the topical treatment of hyperhidrosis (excessive sweating), and chronic migraine headache.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights